Physicochemical Properties
| Molecular Formula | C20H27N3O4 |
| Molecular Weight | 373.453 |
| Exact Mass | 373.2 |
| CAS # | 2093407-25-9 |
| Related CAS # | KY-02327 acetate |
| PubChem CID | 142737047 |
| Appearance | White to off-white solid powder |
| LogP | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 27 |
| Complexity | 510 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(CN1C(C(=O)OCC)=CC2C=C(C=CC1=2)O)NCCN1CCCCC1 |
| InChi Key | NJRAXCQBMGIWEE-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C20H27N3O4/c1-2-27-20(26)18-13-15-12-16(24)6-7-17(15)23(18)14-19(25)21-8-11-22-9-4-3-5-10-22/h6-7,12-13,24H,2-5,8-11,14H2,1H3,(H,21,25) |
| Chemical Name | ethyl 5-hydroxy-1-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]indole-2-carboxylate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Together with Runx2, KY-02327 (1–10 μM; 2 days; MC3T3E1 cells, a mouse preosteoblast cell line) elevates β-catenin protein levels and dose-dependently accumulates nuclear β-catenin [1]. The osteoblast development markers collagen 1a (Col1a) and osteocalcin (OCN) have their mRNA levels increased by KY-02327 (1-10 μM) [1]. |
| ln Vivo | KY-02327 (20 mg/kg; oral; 5 days per week for 4 weeks) successfully recovered bone loss in an ovariectomized (OVX) mice model [1]. |
| Animal Protocol |
Animal/Disease Models: 8weeks old female BL6 mice (ovariectomy (OVX)-induced osteoporosis model mice) [1] Doses: 20 mg/kg Route of Administration: Po; administered 5 days a week for 4 days Experimental Results: Newly formed bone labeled with calcein was diminished in the femurs of vehicle-treated OVX mice. |
| References |
[1]. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~267.77 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.24 mg/mL (11.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.4 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6777 mL | 13.3887 mL | 26.7773 mL | |
| 5 mM | 0.5355 mL | 2.6777 mL | 5.3555 mL | |
| 10 mM | 0.2678 mL | 1.3389 mL | 2.6777 mL |